Asset Details
Do you wish to reserve the book?
Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome
Do you wish to request the book?
Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome
2010
Overview
The investigators induced muscle paralysis in patients with the acute respiratory distress syndrome (ARDS) by administering a neuromuscular blocking agent, cisatracurium besylate. As compared with placebo, cisatracurium resulted in a lower adjusted 90-day mortality without more severe sequelae of neuromuscular blockade.
The acute respiratory distress syndrome (ARDS) is characterized by hypoxemic respiratory failure; it affects both medical and surgical patients.
1
Despite rigorous physiological management,
2
in most studies, ARDS has been fatal in 40 to 60% of patients.
3
–
7
Neuromuscular blocking agents are used in a large but highly variable proportion of patients with ARDS.
8
–
12
Current guidelines indicate that neuromuscular blocking agents are appropriate for facilitating mechanical ventilation when sedation alone is inadequate, most notably in patients with severe gas-exchange impairments.
10
In a four-center randomized, controlled trial of gas exchange in 56 patients with ARDS,
13
infusion of a neuromuscular blocking agent . . .
Publisher
Massachusetts Medical Society
Subject
/ Atracurium - adverse effects
/ Atracurium - analogs & derivatives
/ Atracurium - therapeutic use
/ Biological and medical sciences
/ Humans
/ Neuromuscular Blocking Agents - adverse effects
/ Neuromuscular Blocking Agents - therapeutic use
/ Respiratory distress syndrome
/ Respiratory Distress Syndrome, Adult - drug therapy
/ Respiratory Distress Syndrome, Adult - mortality
